| Autor: |
Tsutomu Nagai, Tatsuya Kurihara, Hiroaki Koya, Yukako Nakano, Satoru Sugisawa, Takehiko Sambe, Keiko Kishimoto, Mari Kogo, Haruhisa Ota, Akira Iwanami, Naoki Uchida |
| Jazyk: |
angličtina |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
Neuropsychopharmacology Reports, Vol 42, Iss 3, Pp 249-255 (2022) |
| Druh dokumentu: |
article |
| ISSN: |
2574-173X |
| DOI: |
10.1002/npr2.12253 |
| Popis: |
Abstract Aim Atomoxetine (ATX) is a non‐central stimulant and a standard treatment for adult attention‐deficit/hyperactivity disorder (ADHD). The long‐term efficacy of Atomoxetine is about 40% at 6 months. The variability in efficacy between individuals is thought to be related to patient‐specific factors, but no detailed research has been conducted. In this retrospective cohort study, we aimed to identify the factors associated with Atomoxetine efficacy. Methods A total of 147 patients with attention‐deficit/hyperactivity disorder aged ≥18 years who were using Atomoxetine for the first time were included in this study. The outcome was treatment success (treatment maintained for at least 6 months and improvement in symptoms). Symptom assessment was based on the overall improvement in symptoms judged by an expert physician. Results Of the patient sample, 103 (70.1%) achieved the outcome. Logistic regression analysis identified “the maximum dose of ATX” and “gambling habit” as factors associated with efficacy ( P |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
|
Nepřihlášeným uživatelům se plný text nezobrazuje |
K zobrazení výsledku je třeba se přihlásit.
|
